Inhibitory Effects of Lapachol on Rat C6 Glioma in Vitro and in Vivo by Targeting DNA Topoisomerase I and Topoisomerase II

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2016 Nov 18

PMID 27852319

Citations 7

Authors

Huanli Xu

Qunying Chen

Hong Wang

Pingxiang Xu

Ru Yuan

Xiaorong Li

Lu Bai

Ming Xue

Affiliations

Soon will be listed here.

Abstract

Background: Lapachol is a natural naphthoquinone compound that possesses extensive biological activities. The aim of this study is to investigate the inhibitory effects of lapachol on rat C6 glioma both in vitro and in vivo, as well as the potential mechanisms.

Methods: The antitumor effect of lapachol was firstly evaluated in the C6 glioma model in Wistar rats. The effects of lapachol on C6 cell proliferation, apoptosis and DNA damage were detected by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)/ phenazinemethosulfate (PMS) assay, hoechst 33358 staining, annexin V-FITC/PI staining, and comet assay. Effects of lapachol on topoisomerase I (TOP I) and topoisomerase II (TOP II) activities were detected by TOP I and TOP II mediated supercoiled pBR322 DNA relaxation assays and molecular docking. TOP I and TOP II expression levels in C6 cells were also determined.

Results: High dose lapachol showed significant inhibitory effect on the C6 glioma in Wistar rats (P < 0.05). It was showed that lapachol could inhibit proliferation, induce apoptosis and DNA damage of C6 cells in dose dependent manners. Lapachol could inhibit the activities of both TOP I and II. Lapachol-TOP I showed relatively stronger interaction than that of lapachol-TOP II in molecular docking study. Also, lapachol could inhibit TOP II expression levels, but not TOP I expression levels.

Conclusion: These results showed that lapachol could significantly inhibit C6 glioma both in vivo and in vitro, which might be related with inhibiting TOP I and TOP II activities, as well as TOP II expression.

Citing Articles

Indium(III) complexes with lapachol: cytotoxic effects against human breast tumor cells and interactions with DNA.

de Carvalho A, Souza A, Bento L, de Oliveira Silva M, Souza-Fagundes E, Diniz R J Biol Inorg Chem. 2024; 29(5):519-529.

PMID: 39009790 DOI: 10.1007/s00775-024-02062-0.

Preclinical evaluation of L-fucoside from lapachol-loaded nanoemulsion as a strategy to breast cancer treatment.

Miranda S, de Alcantara Lemos J, Ottoni F, Cassali G, Townsend D, de Aguiar Ferreira C Biomed Pharmacother. 2023; 170:116054.

PMID: 38150876 PMC: 11878474. DOI: 10.1016/j.biopha.2023.116054.

Development of long-circulating lapachol nanoparticles: formation, characterization, pharmacokinetics, distribution and cytotoxicity.

Chen Q, Bai L, Zhou X, Xu P, Li X, Xu H RSC Adv. 2022; 10(50):30025-30034.

PMID: 35518271 PMC: 9056296. DOI: 10.1039/d0ra05752e.

β-Lapachone Induces Acute Oxidative Stress in Rat Primary Astrocyte Cultures that is Terminated by the NQO1-Inhibitor Dicoumarol.

Steinmeier J, Kube S, Karger G, Ehrke E, Dringen R Neurochem Res. 2020; 45(10):2442-2455.

PMID: 32789798 PMC: 7511478. DOI: 10.1007/s11064-020-03104-0.

Antileishmanial activity of terpenylquinones on Leishmania infantum and their effects on Leishmania topoisomerase IB.

Perez-Pertejo Y, Escudero-Martinez J, Reguera R, Balana-Fouce R, Garcia P, Jambrina P Int J Parasitol Drugs Drug Resist. 2019; 11:70-79.

PMID: 31678841 PMC: 6904838. DOI: 10.1016/j.ijpddr.2019.10.004.

References

Ravelo A, Estevez-Braun A, Chavez-Orellana H, Perez-Sacau E, Mesa-Siverio D . Recent studies on natural products as anticancer agents. Curr Top Med Chem. 2004; 4(2):241-65. DOI: 10.2174/1568026043451500. View

Pistritto G, Trisciuoglio D, Ceci C, Garufi A, DOrazi G . Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies. Aging (Albany NY). 2016; 8(4):603-19. PMC: 4925817. DOI: 10.18632/aging.100934. View

Nakada M, Furuta T, Hayashi Y, Minamoto T, Hamada J . The strategy for enhancing temozolomide against malignant glioma. Front Oncol. 2012; 2:98. PMC: 3418701. DOI: 10.3389/fonc.2012.00098. View

Gomez Castellanos J, Prieto J, Heinrich M . Red Lapacho (Tabebuia impetiginosa)--a global ethnopharmacological commodity?. J Ethnopharmacol. 2008; 121(1):1-13. DOI: 10.1016/j.jep.2008.10.004. View

Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

Fiorito S, Epifano F, Bruyere C, Mathieu V, Kiss R, Genovese S . Growth inhibitory activity for cancer cell lines of lapachol and its natural and semi-synthetic derivatives. Bioorg Med Chem Lett. 2013; 24(2):454-7. DOI: 10.1016/j.bmcl.2013.12.049. View

Costa W, Oliveira A, Nepomuceno J . Lapachol as an epithelial tumor inhibitor agent in Drosophila melanogaster heterozygote for tumor suppressor gene wts. Genet Mol Res. 2011; 10(4):3236-45. DOI: 10.4238/2011.December.22.1. View

Mittal S, Pradhan S, Srivastava T . Recent advances in targeted therapy for glioblastoma. Expert Rev Neurother. 2015; 15(8):935-46. DOI: 10.1586/14737175.2015.1061934. View

Krishnan P, Bastow K . Novel mechanisms of DNA topoisomerase II inhibition by pyranonaphthoquinone derivatives-eleutherin, alpha lapachone, and beta lapachone. Biochem Pharmacol. 2000; 60(9):1367-79. DOI: 10.1016/s0006-2952(00)00437-8. View

10.

Klotz L, Hou X, Jacob C . 1,4-naphthoquinones: from oxidative damage to cellular and inter-cellular signaling. Molecules. 2014; 19(9):14902-18. PMC: 6270801. DOI: 10.3390/molecules190914902. View

11.

Boonyalai N, Sittikul P, Pradidphol N, Kongkathip N . Biophysical and molecular docking studies of naphthoquinone derivatives on the ATPase domain of human topoisomerase II. Biomed Pharmacother. 2012; 67(2):122-8. DOI: 10.1016/j.biopha.2012.08.005. View

12.

Sunassee S, Davies-Coleman M . Cytotoxic and antioxidant marine prenylated quinones and hydroquinones. Nat Prod Rep. 2012; 29(5):513-35. DOI: 10.1039/c2np00086e. View

13.

Asai A, Miyagi Y, Sugiyama A, Gamanuma M, Hong S, Takamoto S . Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy. J Neurooncol. 1994; 19(3):259-68. DOI: 10.1007/BF01053280. View

14.

Ali Y, Abd Hamid S . Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy. Tumour Biol. 2015; 37(1):47-55. DOI: 10.1007/s13277-015-4270-9. View

15.

Xu Y, Her C . Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy. Biomolecules. 2015; 5(3):1652-70. PMC: 4598769. DOI: 10.3390/biom5031652. View

16.

Wang W, Shi G, Ma B, Hao X, Dong X, Zhang B . Chemotherapy for Adults with Malignant Glioma: A Systematic Review and Network Meta-Analysis. Turk Neurosurg. 2016; 27(2):174-181. DOI: 10.5137/1019-5149.JTN.15462-15.0. View

17.

Bai L, Han Y, Yao J, Li X, Li Y, Xu P . Structural elucidation of the metabolites of lapachol in rats by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2013; 944:128-35. DOI: 10.1016/j.jchromb.2013.11.024. View

18.

Li C, Li Y, Pinto A, Pardee A . Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints. Proc Natl Acad Sci U S A. 1999; 96(23):13369-74. PMC: 23954. DOI: 10.1073/pnas.96.23.13369. View

19.

Esteves-Souza A, Figueiredo D, Esteves A, Camara C, Vargas M, Pinto A . Cytotoxic and DNA-topoisomerase effects of lapachol amine derivatives and interactions with DNA. Braz J Med Biol Res. 2007; 40(10):1399-402. DOI: 10.1590/s0100-879x2006005000159. View

20.

An Y, Guo W, Li L, Xu C, Yang D, Wang S . Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo. PLoS One. 2015; 10(2):e0116202. PMC: 4320118. DOI: 10.1371/journal.pone.0116202. View